2. Academic Validation
  3. Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance

Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance

  • Nanomedicine (Lond). 2015;10(13):2033-50. doi: 10.2217/nnm.15.50.
Xiao Su 1,  Hao Song 1 2 3,  Fangfang Niu 1,  Kaixuan Yang 1,  Geng Kou 1 2,  Xiaohang Wang 4,  Huaiwen Chen 1,  Wei Li 1 2,  Shangjing Guo 2,  Jun Li 2,  Bohua Li 1 2,  Si-Shen Feng 1 5 6,  Jianxin Jiang 7,  Chuan Yin 4,  Jie Gao 1 2 8
Affiliations

Affiliations

  • 1 International Joint Cancer Institute, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China.
  • 2 College of Pharmacy, Liaocheng University, 1 Hu'nan Road, Liaocheng, Shandong 25200, PR China.
  • 3 Centre for Stem Cell & Regenerative Medicine, Liaocheng People's Hospital, 67 Dongchang West Road, Liaocheng, Shangdong 252000, China.
  • 4 Department of Gastroenterology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China.
  • 5 Department of Chemical & Biomolecular Engineering, National University of Singapore, Block E5, 02-11, 4 Engineering Drive 4, Singapore 117576, Singapore.
  • 6 Suzhou NanoStar Biopharm Inc Ltd, BioBay, Bld B2, Unit 604, 218 Xing-Hu Street, Suzhou Industrial Park, Suzhou 215123, China.
  • 7 Department of Hepatobiliary Surgery, Hubei Province Tumor Hospital, Wuhan, Hubei 430079, China.
  • 8 Department of Pharmaceutical Sciences, Second Military Medical University, 325 Guohe Road, Shanghai 200433, China.
PMID: 26084553 DOI: 10.2217/nnm.15.50
Abstract

Aim: To develop novel nanoliposomes (Lip-ADR-Cer) codelivering doxorubicin (ADR) and PEGylated C16 ceramide (PEG-ceramide C16) to overcome multidrug resistance.

Materials & methods: The antitumor activity and mechanism of Lip-ADR-Cer were evaluated.

Results & conclusion: The IC50 of Lip-ADR-Cer after 48-h treatment with the MCF-7/ADR and HL-60/ADR Cancer cells, both being ADR resistant, was 2.2- and 1.4-fold effective respectively versus the general nanoliposomes with no PEG-ceramide C16 (Lip-ADR). The antitumor assay in mice bearing MCF-7/ADR or HL-60/ADR xenograft tumors confirmed the superior antitumor activity of Lip-ADR-Cer over Lip-ADR. We found that the improved therapeutic effect of Lip-ADR-Cer may be attributed to both of the cytotoxic effect of PEG-ceramide C16 and glucosylceramide synthase overexpression in multidrug resistance cells.

Keywords

cancer nanotechnology; glucosylceramide synthase; molecular biomaterials; multidrug resistance; nanomedicine; pharmaceutical nanotechnology.

Figures
Products